Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  Cerebrolysin Explained: Research, Evidence & Dosage Guide

Cerebrolysin Explained: Research, Evidence & Dosage Guide

Jun 11, 2026 4 min Cognitive
TL;DR
Cerebrolysin is a mix of small peptides studied for stroke, vascular dementia, traumatic brain injury, and subarachnoid hemorrhage. Multiple Cochrane reviews find the current evidence weak or inconclusive, with some safety concerns noted at higher doses. Robust, well-designed trials are still needed before firm conclusions can be drawn.

What Is Cerebrolysin?

Imagine taking a pig brain, breaking it down into its tiniest building blocks — small peptides and amino acids — and turning those into an injectable solution. That is essentially Cerebrolysin. It is a mix of low-molecular-weight peptides derived from porcine (pig) brain tissue. Researchers believe these peptides may mimic the effects of neurotrophic factors — proteins your brain naturally uses to protect and repair nerve cells.[1]

Cerebrolysin is not a synthetic compound like many drugs. Think of it more like a concentrated biological broth of brain-support molecules. It is given by intravenous (IV) infusion — meaning straight into a vein — and it is widely used as a treatment in Russia, Eastern Europe, China, and other Asian countries.[1] In the West, it remains a research-only substance.

What Are Researchers Studying It For?

Scientists have looked at Cerebrolysin across several serious neurological conditions. Here are the main areas of active investigation:

  • Acute ischaemic stroke — a stroke caused by a blocked blood vessel in the brain[1]
  • Vascular dementia — memory loss and cognitive decline linked to reduced blood flow in the brain[2]
  • Traumatic brain injury (TBI) — brain damage from physical trauma such as a car accident or fall[4]
  • Subarachnoid hemorrhage (SAH) — a type of bleed around the brain, often from a ruptured aneurysm[6]

The core idea behind all this research is the same: could Cerebrolysin protect nerve cells from dying after a brain injury or disease, and could it support recovery?

What Does the Evidence Actually Show?

Stroke

This is the most studied area. A 2023 Cochrane review — Cochrane reviews are the gold standard of evidence summaries — pooled data from seven randomised controlled trials involving 1,773 participants. The verdict? Cerebrolysin probably makes little to no difference in preventing death after acute ischaemic stroke.[1] The evidence quality was rated as moderate. There was also a notable finding around safety: the same review found a potential increase in non-fatal serious adverse events, particularly at a cumulative dose of 300 mL (30 mL per day for 10 days).[1] An earlier 2020 Cochrane update reached similar conclusions.[3]

Vascular Dementia

A 2019 Cochrane review of six trials with 597 participants found that Cerebrolysin did show a statistically measurable improvement in cognitive function and global function in people with vascular dementia.[2] Sounds promising — but the researchers immediately flagged the evidence quality as very low. The included studies had a high risk of bias, and the size of the benefit may be too small to matter clinically. The reviewers concluded that better, larger trials are urgently needed.[2]

Traumatic Brain Injury (TBI)

A 2023 systematic review and meta-analysis examined Cerebrolysin specifically in TBI patients. Researchers found some signals suggesting potential benefit for neurological outcomes, but again the overall quality of the available data was limited.[4] TBI research is particularly challenging because injuries vary enormously from person to person.

Subarachnoid Hemorrhage

A 2023 meta-analysis looked at Cerebrolysin in patients who had suffered a subarachnoid hemorrhage. Early findings were cautiously exploratory — the research team noted potential areas of interest but stressed that the evidence base remains immature and more rigorous trials are needed.[6]

The Bottom Line on Evidence

Across all these conditions, a pattern emerges: intriguing signals, but weak or inconclusive proof. The Cochrane reviews — the most rigorous evidence summaries available — consistently rate the evidence as very low to moderate quality. Many included studies carry a high risk of bias, and some were funded by the manufacturer of Cerebrolysin.[1][2] That does not mean the research is wrong, but it does mean we should interpret results with caution.

The safety picture also warrants attention. The stroke Cochrane review flagged a possible increase in non-fatal serious adverse events at higher cumulative doses.[1] This is exactly why understanding dosage parameters used in research matters — check our calculator to explore how researchers have structured dosing protocols in studies.

Where to Find the Research Dosage Data

If you are a researcher, clinician, or simply curious about what doses have been used in published studies, our Cerebrolysin dosage chart breaks down the protocols from the peer-reviewed literature in one easy-to-read reference. Remember: this site is for research and educational purposes only — nothing here is medical advice.

Sources

  1. Cerebrolysin for acute ischaemic stroke. — The Cochrane database of systematic reviews, 2023. PMID 37818733.
  2. Cerebrolysin for vascular dementia. — The Cochrane database of systematic reviews, 2019. PMID 31710397.
  3. Cerebrolysin for acute ischaemic stroke. — The Cochrane database of systematic reviews, 2020. PMID 32662068.
  4. Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis. — Brain sciences, 2023. PMID 36979317.
  5. Cerebrolysin for acute ischaemic stroke. — The Cochrane database of systematic reviews, 2017. PMID 28430363.
  6. Cerebrolysin in Patients with Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis. — Journal of clinical medicine, 2023. PMID 37892776.
See the dosage chart — Cerebrolysin
A peptide preparation studied for neuroprotection and recovery.
Cerebrolysin

FAQ

What exactly is Cerebrolysin made from?
Cerebrolysin is a mixture of small peptides and free amino acids extracted from porcine (pig) brain tissue. Researchers believe these molecules may act similarly to natural neurotrophic factors — proteins the brain uses to protect and maintain nerve cells. It is administered by intravenous infusion in clinical and research settings.
Has Cerebrolysin been proven to work for stroke?
Not conclusively. A 2023 Cochrane review of seven randomised trials found moderate-certainty evidence that Cerebrolysin probably makes little to no difference in preventing death after acute ischaemic stroke. It also flagged a potential increase in non-fatal serious adverse events at higher doses. Better trials are still needed before any firm conclusions can be drawn.
Is Cerebrolysin safe?
Safety signals have been noted in research. The most recent Cochrane stroke review found a statistically significant increase in non-fatal serious adverse events with Cerebrolysin compared to placebo, particularly at a cumulative 300 mL dose. However, total adverse event rates were broadly similar. This is an active area of scrutiny and underscores the need for careful dosage research.
What conditions is Cerebrolysin being researched for right now?
Current research focuses primarily on acute ischaemic stroke, vascular dementia, traumatic brain injury, and subarachnoid hemorrhage. Across all these areas, early signals exist but the evidence quality is generally rated as low to moderate by systematic reviewers. Larger, well-designed randomised controlled trials are considered necessary before clinical conclusions can be made.
For research and educational use only. Not medical advice.